TriSalus Life Sciences (TLSI) Stock Forecast, Price Target & Predictions
TLSI Stock Forecast
TriSalus Life Sciences stock forecast is as follows: an average price target of $10.50 (represents a 154.24% upside from TLSI’s last price of $4.13) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
TLSI Price Target
The average price target for TriSalus Life Sciences (TLSI) is $10.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $10.00. This represents a potential 154.24% upside from TLSI's last price of $4.13.
TLSI Analyst Ratings
According to 2 Wall Street analysts, TriSalus Life Sciences's rating consensus is 'Buy'. The analyst rating breakdown for TLSI stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
TriSalus Life Sciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | William Plovanic | Canaccord Genuity | $11.00 | $4.11 | 167.64% | 166.34% |
| Sep 16, 2024 | Suraj Kalia | Oppenheimer | $10.00 | $4.52 | 121.24% | 142.13% |
| Jul 02, 2024 | William Plovanic | Canaccord Genuity | $12.00 | $5.33 | 125.14% | 190.56% |
The latest TriSalus Life Sciences stock forecast, released on Nov 15, 2024 by William Plovanic from Canaccord Genuity, set a price target of $11.00, which represents a 167.64% increase from the stock price at the time of the forecast ($4.11), and a 166.34% increase from TLSI last price ($4.13).
TriSalus Life Sciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $11.00 | $11.00 |
| Last Closing Price | $4.13 | $4.13 | $4.13 |
| Upside/Downside | -100.00% | 166.34% | 166.34% |
In the current month, the average price target of TriSalus Life Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to TriSalus Life Sciences's last price of $4.13. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 15, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Sep 16, 2024 | Oppenheimer | Outperform | Initialise | |
| Jul 02, 2024 | Canaccord Genuity | Buy | Buy | Hold |
TriSalus Life Sciences's last stock rating was published by Canaccord Genuity on Nov 15, 2024. The company gave TLSI a "Buy" rating, the same as its previous rate.
TriSalus Life Sciences Financial Forecast
TriSalus Life Sciences Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $28.78M | $27.72M | $25.59M | $24.52M | $22.83M | $21.99M | $20.30M | $19.45M | $13.29M | $11.80M | $10.58M | $9.21M | $8.05M | $7.38M | $6.88M | $6.17M | $5.45M |
| High Forecast | $30.23M | $29.11M | $26.87M | $25.75M | $23.98M | $23.09M | $21.32M | $20.43M | $13.96M | $12.40M | $11.11M | $9.51M | $8.32M | $7.75M | $6.88M | $6.48M | $5.73M |
| Low Forecast | $26.99M | $25.99M | $24.00M | $23.00M | $21.41M | $20.62M | $19.03M | $18.24M | $12.47M | $11.07M | $9.92M | $8.82M | $7.90M | $6.92M | $6.88M | $5.78M | $5.11M |
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
TriSalus Life Sciences's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. TLSI's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
TriSalus Life Sciences EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-28.78M | $-27.72M | $-25.59M | $-24.52M | $-22.83M | $-21.99M | $-20.30M | $-19.45M | $-13.29M | $-11.80M | $-10.58M | $-9.21M | $-8.05M | $-7.38M | $-6.88M | $-6.17M | $-5.45M |
| High Forecast | $-26.99M | $-25.99M | $-24.00M | $-23.00M | $-21.41M | $-20.62M | $-19.03M | $-18.24M | $-12.47M | $-11.07M | $-9.92M | $-8.82M | $-7.90M | $-6.92M | $-6.88M | $-5.78M | $-5.11M |
| Low Forecast | $-30.23M | $-29.11M | $-26.87M | $-25.75M | $-23.98M | $-23.09M | $-21.32M | $-20.43M | $-13.96M | $-12.40M | $-11.11M | $-9.51M | $-8.32M | $-7.75M | $-6.88M | $-6.48M | $-5.73M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict TLSI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than TriSalus Life Sciences's previous annual EBITDA (undefined) of $NaN.
TriSalus Life Sciences Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | $-2.06M | $-3.18M | $-4.18M | $-5.46M | $-8.22M | $-9.19M | $-12.17M | $-15.37M | $-18.29M |
| High Forecast | - | - | - | - | - | - | - | - | $-1.90M | $-2.92M | $-3.85M | $-1.98M | $-7.51M | $-8.44M | $-11.19M | $-14.13M | $-16.81M |
| Low Forecast | - | - | - | - | - | - | - | - | $-2.20M | $-3.39M | $-4.46M | $-7.69M | $-8.92M | $-9.79M | $-12.97M | $-16.38M | $-19.48M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
TriSalus Life Sciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TLSI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
TriSalus Life Sciences SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $62.27M | $59.96M | $55.35M | $53.04M | $49.39M | $47.56M | $43.90M | $42.07M | $28.76M | $25.53M | $22.89M | $19.93M | $17.40M | $15.96M | $14.88M | $13.34M | $11.80M |
| High Forecast | $65.40M | $62.98M | $58.13M | $55.71M | $51.87M | $49.95M | $46.11M | $44.19M | $30.20M | $26.81M | $24.04M | $20.57M | $17.99M | $16.76M | $14.88M | $14.01M | $12.39M |
| Low Forecast | $58.40M | $56.23M | $51.91M | $49.74M | $46.32M | $44.60M | $41.17M | $39.46M | $26.97M | $23.94M | $21.46M | $19.08M | $17.08M | $14.97M | $14.88M | $12.51M | $11.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
TriSalus Life Sciences's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to TLSI last annual SG&A of $NaN (undefined).
TriSalus Life Sciences EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | $-0.08 | $-0.12 | $-0.16 | $-0.21 | $-0.31 | $-0.35 | $-0.46 | $-0.58 | $-0.69 |
| High Forecast | - | - | - | - | - | - | - | - | $-0.07 | $-0.11 | $-0.15 | $-0.07 | $-0.28 | $-0.32 | $-0.42 | $-0.53 | $-0.63 |
| Low Forecast | - | - | - | - | - | - | - | - | $-0.08 | $-0.13 | $-0.17 | $-0.29 | $-0.34 | $-0.37 | $-0.49 | $-0.62 | $-0.74 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, TriSalus Life Sciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TLSI previous annual EPS of $NaN (undefined).